This year, a well-established IT company from Slovakia ESET launched a prestigious ESET Science Award for exceptional scientists to increase the popularity of excellent scientists. Among all the scientists nominated, the winner of the main category and recipient of 100 000 € became Jan Tkac, CSO and co-founder of the Glycanostics company. All finalists were carefully chosen and a winner was announced based on a recommendation of a panel of international experts, including Nobel prize laureate Erwin Neher.
“He focuses on the research of glycans for the diagnosis of some oncological diseases. What he appreciates about science is freedom. He sees in it not only the collection of knowledge and skills, but also the possibility to use them. He admires those types of people who motivate others to use their full potential effectively, such as Greta Thunberg and Peter Sagan. What is more important than trying to live a long life is doing everything we can to protect our blue planet from becoming overcrowded, too warm, dry or wet soon.”
– writes ESET about Jan.
Moreover, Tomas Bertok, a co-founder of the company Glycanostics was listed in the Top 5 finalists for the category under 35 years of age.
Means and methods for glycoprofiling of a protein
Glycanostics successfully finished the first phase of SME Instrument
After receiving the prestigious “Seal of Excellence” on October 23, the next submission to the Horizon 2020 Programme, won a € 50 000 grant.
This project received the highest scores for its proposal in the extremely competitive evaluation process.
Glycanostics was chosen as a finalist in the Grand Finale with five other remarkable startups.
The application covering Glycanostics' diagnostic method is currently filed in two patent offices in Europe and Luxemburg.
Glycanoctics innovations are again supported and highly ranked by leading industry experts. This time the company won the European Research Council (ERC) Proof of Concept Grant.
The competition's objectives are to actively support innovative projects with high market potential
In April 2018 the technology validation was successfully completed indicating a great potential of Glycanostics innovative products for prostate cancer (PCa) diagnostics.
Glycanostics is an innovative start-up company established in 2017 to bring its revolutionary cancer diagnostics products to the US and EU markets.